openPR Logo
Press release

Impact of COVID-19 on Cancer Vaccines Market to growing at CAGR of 17.7% by 2023, Top Prominent Players: Astrazeneca Plc., Glaxosmithkline Plc

07-30-2020 02:38 PM CET | Health & Medicine

Press release from: Allied Market Research

Cancer Vaccines Market

Cancer Vaccines Market

UPDATE AVAILABLE ON-DEMAND

The global cancer vaccines market was valued at $4,073 million in 2016, and is projected to reach at $12,814 million by 2023, growing at a CAGR of 17.7% from 2017 to 2023.

Global Cancer Vaccines Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly changing market scenarios and their impact are covered in the report.

Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/1453

The recombinant cancer vaccines segment accounted for one-third share of the global market in 2016.

Vaccines include antigenic components, which strengthens an individuals immune system by developing adaptive immunity to prevent morbidity from infections. Cancer vaccine is a type of immunotherapy that boost the bodys natural defenses by stimulating the immune system to recognize and cure cancerous cells.

The global market is driven by rise in prevalence of HPV infections and related cancer, increase in administration of prophylactic cancer vaccines, surge in investments & findings in the development of cancer vaccines, and launch of novel cancer vaccines in the market. However, longer timelines required for manufacturing a single vaccine restrain the development of new vaccines; thereby, hampering the market growth. In addition, high monetary inputs for the development of cancer vaccines decrease their adoption in the market; thereby, hampering the market growth.

The cervical cancer segment accounted for maximum market revenue in 2016, and is anticipated to maintain its dominant position during the forecast period, owing to the increase in number of people suffering from human papilloma virus (HPV) infections, which causes approximately 70% of cervical cancers globally. In addition, high prevalence of cervical, prostate, lungs, and breast cancer among adults propel the market growth. However, prostate cancer is growing at the highest CAGR of 18.6% from 2017 to 2023, owing to the increase in demand for Provenge (prostate cancer vaccine) along with the increase in number of prostate cancer vaccines in the pipeline.

The recombinant cancer vaccines segment dominated the global market in 2016, and is expected to maintain its dominance throughout the forecast period. This is attributed to the large number of approved cancer vaccines developed using recombinant technology such as Cervarix, Gardasil, and Recombivax HB. The therapeutic cancer vaccines segment is anticipated to register the highest growth rate during the forecast period, owing to the increase in transition from prophylactic cancer vaccines to therapeutic cancer vaccines.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/1453

The adult cancer vaccine segment dominated the end use market, accounting for about fifth-eighths share of the global market in 2016, due to the increase in incidence of HPV infections, breast cancers, and prostate cancers among adults. Moreover, active government participation for provision of vaccination to all children has augmented the market growth.

Asia-Pacific witnessed the highest growth rate for cancer vaccines in 2016, and is expected to continue this trend throughout the forecast period. This is attributed to large population base, rise in incidence of HPV infection related cancers & other cancer cases, healthcare infrastructural development, and huge market potential. Moreover, the introduction of novel preventive, therapeutic, and adult cancer vaccines in the market along with the increasing focus by key players in the emerging markets has fueled the growth of the industry.

The key players operating in the vaccines market have adopted product launch as their key developmental strategy and focus on launching innovative products to cater to the consumer requirements and strengthen their market shares.

The major companies profiled Are:

Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.

The other key players Are:

Gritstone Oncology, PaxVax Corporation., Bavarian Nordic, Bharat Biotech., VBI Vaccines Inc., Novavax, Inc., Dynavax Technologies Corporation, Immunomic Therapeutics, Inc., Gamma Vaccines Pty Limited, Sinovac Biotech Ltd., Galena Biopharma, Emergent Biosolutions, Prokarium, and ImmunoBiology Ltd.

Access Full Report @ https://www.alliedmarketresearch.com/cancer-vaccines-market

Contact:

David Correa
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Impact of COVID-19 on Cancer Vaccines Market to growing at CAGR of 17.7% by 2023, Top Prominent Players: Astrazeneca Plc., Glaxosmithkline Plc here

News-ID: 2099852 • Views: 700

More Releases from Allied Market Research

Ultrasonic Air Bubble Detectors Market Size & Share | Analysis - 2026
UPCOMING REPORT’S INTRODUCTION: According to an upcoming report of Allied Market Research, titled, “Ultrasonic Air Bubble Detectors Market”, the Ultrasonic Air Bubble Detectors market is expected to grow sustainably from 2020 to 2027. The report offers a comprehensive analysis of various growth drivers of the Ultrasonic Air Bubble Detectors market. The analysis ranges from revenue and operations to future growth opportunities. This comprehensive analysis of great importance for stakeholders to
World GPS Tracking Device Market - Opportunities and Forecasts, 2020-2027
Analyzing the current situation of pandemic, Allied market research has published a report t, which says, the GPS Tracking Device market is expected to grow at a faster pace by 2027. The researchers have intelligently made analysis and forecasts of the future growth by taking the past performance and data into consideration. The analysis offered by the report will surely provide valuable insights to the stakeholders of the GPS Tracking
Automotive Smart Helmet Market Statistics 2020: Advanced Technologies, Trends, C …
Allied Market Research published a new report, titled, "Automotive Smart Helmet Market." The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter's Five Forces analysis, and competitive landscape. This study is a helpful source of information for market players, investors, VPs, stakeholders, and new entrants to gain thorough understanding of the industry and determine steps to be taken to gain competitive advantage. Get detailed COVID-19 impact
Hybrid Funds Market Size, Share and Growth | Analysis - 2027
INTRODUCTION TO REPORT The report published by Allied market research, titled, “Hybrid Funds Market”, offers a comprehensive analysis of key growth drivers, key segments, development strategies, market opportunities, and competitive landscape. This study offers detailed insights for market players, investors, stakeholders, and new entrants to understand the industry dynamics and determine strategic steps to gain the competitive advantage. COVID_19 Scenarios: The Hybrid Funds has been the worst hit by COVID-19 globally. Based

All 5 Releases


More Releases for Vaccines

Global Influenza Vaccines Market
Global Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027 Worldwide Influenza Vaccines Market size is expected to exceed USD 7.5 billion by 2027. The report contains a deep analysis of the worldwide influenza vaccines market with size in terms of both value and volume. The report provides a clear insight into current and future developments of the worldwide influenza vaccines market. The report also explores a detailed analysis
Designing multi-purpose vaccines
Scientists from the five year EU funded project MycoSynVac report their findings and successes at a final meeting in Brussels. The project drew on cutting edge biotechnology to explore three important GOALS: 1. TRANSFORM a living bacteria (Mycoplasma pneumoniae) into a vaccine chassis 2. APPLY this vaccine chassis against bacterial diseases in livestock animals, 3. CONTRIBUTE to the reduction of antibiotics administered to farm animals A well-rounded approach to science featuring
Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Animal Vaccines Market Report 2018: Segmentation by Product (Attenuated Vaccines …
Global Animal Vaccines market research report provides company profile for Merck & Co., Inc., Zoetis Inc., Ceva Sant Animale, Sanofi S.A., Romvac, Vaxxinova, Biovac, Merial, Anicon Labor GmbH, Nexvet, PHL Associates, Inc., Hygieia Biological Laboratories, Colorado Serum Company, Pfizer, Arko Laboratories, Ltd. Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in
Vaccines & Vaccination Market Report 2018: Segmentation by Type (Subunit vaccine …
Global Vaccines & Vaccination market research report provides company profile for CSL, Emergent BioSolutions, GSK, Johnson & Johnson, Pfizer, Merck, Sanofi, Abbott, AstraZeneca, Bavarian Nordic, Novartis, Bharat Biotech, Bio-Med and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year
Global Veterinary Vaccines Market
The Global Veterinary Vaccines Market was valued at US$ 5,688.7 million in 2015 and is projected to expand at a CAGR of 5.9% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Rise in incidence of food-borne zoonotic diseases along with increase in population of livestock is expected to favor growth of the veterinary vaccines market. According to European food safety authority (EFSA),